Molecular Pathobiology of Gastrointestinal Stromal ... - ResearchGate

Molecular Pathobiology of Gastrointestinal Stromal ... - ResearchGate

Annu. Rev. Pathol. Mech. Dis. 2008.3:557-586. Downloaded from

by Oregon Health & Science University on 02/02/08. For personal use only.

40. Chian R, Young S, Danilkovitch-Miagkova A, Ronnstrand L, Leonard E, et al. 2001.

Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells

by the D816V c-Kit mutant. Blood 98:1365–73

41. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, et al. 2004. Structural basis

for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem.


42. Mol CD, Lim KB, Sridhar V, Zou H, Chien EY, et al. 2003. Structure of a c-kit product

complex reveals the basis for kinase transactivation. J. Biol. Chem. 278:31461–64

43. Foster R, Griffith R, Ferrao P, Ashman L. 2004. Molecular basis of the constitutive

activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.

J. Mol. Graph. Model. 23:139–52

44. Xiang Z, Kreisel F, Cain J, Colson A, Tomasson MH. 2007. Neoplasia driven by mutant

c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol. Cell

Biol. 27:267–82

45. Liu H, Chen X, Focia PJ, He X. 2007. Structural basis for stem cell factor-KIT signaling

and activation of class III receptor tyrosine kinases. EMBO J. 26:891–901

46. Bauer S, Yu LK, Demetri GD, Fletcher JA. 2006. Heat shock protein 90 inhibition in

imatinib-resistant gastrointestinal stromal tumor. Cancer Res. 66:9153–61

47. Fumo G, Akin C, Metcalfe DD, Neckers L. 2004. 17-Allylamino-17-

demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively

activated KIT protein in human mast cells. Blood 103:1078–84

48. Pauls K, Merkelbach-Bruse S, Thal D, Buttner R, Wardelmann E. 2005. PDGFRα- and

c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive

histological and immunohistochemical features. Histopathology 46:166–75

49. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, et al. 2003. PDGFRA

activating mutations in gastrointestinal stromal tumors. Science 299:708–10

50. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, et al. 2003. Gain-of-function

mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal

tumors. Gastroenterology 125:660–67

51. Wasag B, Debiec-Rychter M, Pauwels P, Stul M, Vranckx H, et al. 2004. Differential

expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of

gastrointestinal stromal tumors depends predominantly on the tumor site. Mod. Pathol.


52. Kang HJ, Nam SW, Kim H, Rhee H, Kim NG, et al. 2005. Correlation of KIT and

platelet-derived growth factor receptor α mutations with gene activation and expression

profiles in gastrointestinal stromal tumors. Oncogene 24:1066–74

53. Chompret A, Kannengiesser C, Barrois M, Terrier P, Dahan P, et al. 2004. PDGFRA

germline mutation in a family with multiple cases of gastrointestinal stromal tumor.

Gastroenterology 126:318–21

54. de Raedt T, Cools J, Debiec-Rychter M, Brems H, Mentens N, et al. 2006. Intestinal

neurofibromatosis is a subtype of familial GIST and results from a dominant activating

mutation in PDGFRA. Gastroenterology 131:1907–12

55. Matei D, Satpathy M, Cao L, Lai YC, Nakshatri H, Donner DB. 2007. The plateletderived

growth factor receptor α is destabilized by geldanamycins in cancer cells. J. Biol.

Chem. 282:445–53

56. Debiec-Rychter M, Wasag B, Stul M, De WI, Van Oosterom A, et al. 2004. Gastrointestinal

stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.

J. Pathol. 202:430–38

580 Corless·Heinrich

More magazines by this user
Similar magazines